GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan to enter a longer-term collaboration later this year to discover novel cannabinoids for use in pain and central nervous system disorders.
You may also be interested in...
GW Insists Sativex Is Approvable In U.K. Despite Phase III Failure In MS Pain
British pharma pulls application for MS spasticity but says it will re-file in U.K. after confirmatory study.
GW Insists Sativex Is Approvable In U.K. Despite Phase III Failure In MS Pain
British pharma pulls application for MS spasticity but says it will re-file in U.K. after confirmatory study.
Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus
Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.